Clinical Policy Title: West Nile virus
|
|
- Annabelle Hopkins
- 5 years ago
- Views:
Transcription
1 Clinical Policy Title: West Nile virus Clinical Policy Number: Effective Date: October 1, 2016 Initial Review Date: July 20, 2016 Most Recent Review Date: July 20, 2016 Next Review Date: July 2017 Related policies: Policy contains: West Nile virus Immunoglobulin M antibody testing. Reverse transcriptase-polymerase chain reaction testing. Plaque-reduction neutralization testing. CP# CP# Zika virus Prenatal obstetrical ultrasound ABOUT THIS POLICY: Keystone First has developed clinical policies to assist with making coverage determinations. Keystone First s clinical policies are based on guidelines from established industry sources, such as the Centers for Medicare & Medicaid Services (CMS), state regulatory agencies, the American Medical Association (AMA), medical specialty professional societies, and peer-reviewed professional literature. These clinical policies along with other sources, such as plan benefits and state and federal laws and regulatory requirements, including any state- or plan-specific definition of medically necessary, and the specific facts of the particular situation are considered by Keystone First when making coverage determinations. In the event of conflict between this clinical policy and plan benefits and/or state or federal laws and/or regulatory requirements, the plan benefits and/or state and federal laws and/or regulatory requirements shall control. Keystone First s clinical policies are for informational purposes only and not intended as medical advice or to direct treatment. Physicians and other health care providers are solely responsible for the treatment decisions for their patients. Keystone First s clinical policies are reflective of evidence-based medicine at the time of review. As medical science evolves, Keystone First will update its clinical policies as necessary. Keystone First s clinical policies are not guarantees of payment. Coverage policy Care management of persons with West Nile virus (WNV) exposure or illness is evolving. In instances where Keystone First policies and Centers for Disease Control and Prevention (CDC) guidelines conflict, CDC guidance will govern. A. Keystone First considers the following over-the-counter (OTC) services to be medically necessary up to plan limit in at-risk areas: Medications to relieve symptoms such as pain and fever. Environmental Protection Agency (EPA)-registered insect repellents when used as directed. EPA-registered insect repellents contain one of the following active ingredients: DEET, picaridin, IR3535, oil of lemon eucalyptus, or para-menthanediol. They are proven safe and effective when used as directed, even for pregnant and breastfeeding women. See searchable database of EPA-registered insect repellents: 1
2 See other CDC prevention guidelines: B. Keystone First considers the use of WNV testing to be clinically proven and, therefore, medically necessary when performed in accordance with CDC guidelines: Indications for WNV testing: Symptomatic individuals as part of the differential diagnosis of febrile or acute neurologic illnesses associated with recent WNV exposure to mosquitoes, blood transfusion or organ transplantation. Neonates whose mothers were infected with WNV during pregnancy or while breastfeeding. Test selection should consider the range of pathogens in the differential diagnosis, the criteria for classifying a WNV case as confirmed or probable, and the capability of the primary and confirming diagnostic laboratories: Antibody testing: WNV immunoglobulin M (IgM) or immunoglobulin G (IgG) of serum or cerebrospinal fluid (CSF) within eight days of illness onset (WNV IgM preferred) using Food and Drug Administration (FDA)-approved commercial test kits or CDC-defined IgM and IgG enzyme-linked immunosorbent assay (ELISA) testing. Convalescent phase serum testing to confirm negative screen or retrospective diagnosis of infection with a specific agent. Plaque reduction neutralization test (PRNT) to confirm positive screen. Virus isolation of CSF, serum or tissue. WNV ribonucleic acid (RNA) testing (e.g., reverse transcriptase-polymerase chain reaction [RT-PCR]) to confirm diagnosis in acute-phase serum, CSF or tissue specimens, and to screen transplant donors in at-risk areas. Required documentation includes: 1) symptom onset date (when known); 2) date of sample collection; 3) unusual immunological status of patient (e.g., immunosuppression); 4) state and county of residence; 5) travel history (especially in flavivirus-endemic areas); 6) history of prior vaccination (e.g., yellow fever, Japanese encephalitis, or Tick-borne encephalitis viruses); and 7) brief clinical summary including clinical diagnosis (e.g., encephalitis, aseptic meningitis). C. Keystone First considers the following services to be clinically proven and, therefore, medically necessary when performed in accordance with CDC WNV guidelines: Prenatal obstetrical ultrasound of the fetus with no upper limit on the number of tests, no sooner than two to four weeks after onset of WNV illness in the mother, unless earlier examination is otherwise indicated. For infants born to a mother with known or suspected WNV infection during pregnancy, IgM and IgG antibody serum testing and neurological and hearing examinations (See Appendix Box 1). For infants born with suspected or clinical/laboratory evidence of WNV infection, brain imaging, ophthalmalogical (including retina) evaluation, WMV IgM antibody testing of CSF, hearing 2
3 screen, IgM/IgG antibody testing at six months and further examination of abnormalities as needed (See Appendix Box 2). Histopathologic evaluation of the placenta and umbilical cord (See Appendix Boxes 1 and 2). Limitations: The following services are not medically necessary: Vaccines to prevent WNV infection, as their clinical benefit has not been established. Screening asymptomatic individuals for WNV due to the high portion of infected individuals who are asymptomatic with no associated health problems. Treatment for WNV illness using antiviral agents, nucleic acid analogues, missense sequences, immunomodulating agents and angiotensin-receptor blockers, as their clinical benefit has not been established. For Medicare members only: Keystone First considers the use of intravenous immunoglobulin to be medically necessary when used in the treatment of WNV infection, including meningitis and encephalitis. Alternative covered services: Standard of care for clinical examination and differential diagnosis (e.g, testing for flavivirus infection, brain imaging and ophthalmic and neurological examination). Supportive in-hospital care. Physical therapy and occupational therapy. Background WNV emerged in North America in 1999 and is most commonly spread by infected Culex mosquitoes (Centers for Disease Control and Prevention [CDC] 2015a). In a very small number of cases, WNV has spread through blood transfusions, organ transplants and from mother to baby during pregnancy, delivery or breastfeeding. As an arbovirus, WNV is a nationally notifiable condition. Arboviruses occur sporadically, and the epidemiology varies by virus and geographic area. WNV has been detected in all lower 48 states. WNV has followed a pattern of low disease intensity with periodic major epidemics with incidence peaking in and again in In ,060 cases of WNV were reported to CDC, of which 1,360 cases (66 percent) were classified as neuroinvasive disease (CDC 2015a). An incubation period of 3 14 days precedes symptoms, but most people (70-80 percent) who become infected with WNV remain asymptomatic. The rest may present with abrupt onset of common nonspecific symptoms such as fever, headache, altered mental status, vomiting, diarrhea and 3
4 maculopapillary rash (DeBiasi 2006). Less than one percent of people who are infected will develop a serious neurologic illness, and about 10 percent of those will die of the infection (CDC 2015a). Clinical syndromes associated with WNV include West Nile fever (WNF), West Nile neuroinvasive disease (encephalitis, meningitis, poliomyelitis and other forms of acute flaccid paralysis) and ocular manifestations (e.g., chorioretinitis and vitritis); case reports of numerous other clinical manifestations have been described in association with WNV infection (Sejvar 2014). Most children with symptomatic WNV infection present with WNF; of those who develop neuroinvasive disease, meningitis is the most frequent manifestation. West Nile encephalitis is more typically manifested in older or immunocompromised individuals. Severity of neurologic illness at initial presentation does not necessarily correlate with eventual outcome. While most recover completely, recovery from severe disease may take several weeks or months, and some of the neurologic effects may be permanent (CDC 2015a). Limited data indicate muscle weakness, memory loss and difficulties with activities of daily living were among the most common long-term physical, cognitive and functional sequelae, respectively (Patel 2015). Key risk factors for developing neuroinvasive disease include increasing age, underlying morbidity (cardiovascular disease or cancer), immune status and specific genetic factors often linked with innate and acquired immunity (Tyler 2014, Patel 2015). Detection and diagnosis: Diagnosis is based on clinical symptoms, laboratory testing, recent exposure and vaccination history. Laboratory diagnosis includes detection of viable WNV, WNV RNA and WNV-specific antibodies. Laboratory diagnosis is generally accomplished by testing for WNV-specific IgM antibodies in serum or CSF, WNV IgG antibody testing, PRNTs and virus cultures of CSF. Nucleic acid amplification tests (NAATs) (e.g., RT-PCR) in serum, CSF and tissue specimens amplify and measure genetic material to detect the presence of WNV RNA. NAATs are routinely used to screen units of donated blood for WNV and may be performed on the blood of tissue and organ donors prior to transplantation. NAATs and viral cultures are used frequently in research settings. Immunoassays for WNV-specific IgM are available commercially and through state public health laboratories. FDA has approved four commercially-available test kits from different manufacturers for detection of WNV IgM and IgG antibodies, and CDC-defined IgM and IgG enzyme-linked immunosorbent assay (ELISA) may be used (Table 1) (CDC 2013a, FDA 2016). Table 1. Characteristic sensitivity and time required for WNV virus or viral RNA human detection assays 1 4
5 Test Detects Detection level (plaque forming Assay time units [pfu]/ml) Virus isolation in suckling mouse Infectious virus days Virus isolation in Vero cell culture Infectious virus days Standard RT-PCR Viral RNA 5 8 hours Nucleic Acid Sequence-based Amplification (NASBA) Viral RNA hours TaqMan RT-PCR Viral RNA hours Transcription Mediated Amplification Viral RNA hours 1 Adapted from CDC (2013). Searches Keystone First searched PubMed and the databases of: UK National Health Services Centre for Reviews and Dissemination. Agency for Healthcare Research and Quality s National Guideline Clearinghouse and other evidence-based practice centers. The Centers for Medicare & Medicaid Services (CMS). We conducted searches on June 13, Search terms were: "West Nile virus"[mesh]), "West Nile Virus vaccines"[mesh], West Nile fever and the free text term West Nile virus. We included: Findings Systematic reviews, which pool results from multiple studies to achieve larger sample sizes and greater precision of effect estimation than in smaller primary studies. Systematic reviews use predetermined transparent methods to minimize bias, effectively treating the review as a scientific endeavor, and are thus rated highest in evidence-grading hierarchies. Guidelines based on systematic reviews. Economic analyses, such as cost-effectiveness, and benefit or utility studies (but not simple cost studies), reporting both costs and outcomes sometimes referred to as efficiency studies which also rank near the top of evidence hierarchies. One literature review by CDC (2015b) and six evidence-based guidelines from CDC (2004, 2013b and 2015c), the Infectious Disease Society of America (IDSA) (Tunkel, 2008), the American College of Radiologists (ACR) (ACR 2014) and the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology (ASRMS) (2008) provide the basis for this policy. WNV disease should be considered in the differential diagnosis of febrile or acute neurologic illnesses associated with recent exposure to mosquitoes, blood transfusion or organ transplantation, and of illnesses in neonates whose mothers were infected with WNV during pregnancy or while breastfeeding. Numerous pathogens cause encephalitis, aseptic meningitis and febrile disease with clinical presentations similar to those caused by WNV and should be considered in the differential diagnosis. 5
6 Testing should be performed in symptomatic individuals, not for screening asymptomatic individuals due to the high proportion of infected individuals who are asymptomatic with no associated health problems. Selection of diagnostic test procedures should take into consideration the range of pathogens in the differential diagnosis, the criteria for classifying a WNV case as confirmed or probable, as well as the capability of the primary and confirming diagnostic laboratories. WNV IgM antibody testing in serum or CSF is preferred to initially screen for WNV infections. The sensitivity of PCR testing is inferior to IgM testing, as peak viremia occurs three to four days before symptom onset. WNV-specific IgM antibodies are usually detectable in the acute phase three to eight days after onset of symptoms and persist for 30 to 90 days and possibly longer. The presence of virusspecific IgM in CSF is usually indicative of neuroinvasive disease, because IgM antibodies do not readily diffuse across the blood-brain barrier. If serum is collected within eight days of illness onset, the absence of detectable virus-specific IgM does not rule out infection, and the test may need to be repeated on a later sample. In general, IgG antibodies are detectable shortly after the appearance of IgM antibodies and persist for years following a symptomatic or asymptomatic infection. The presence of IgG antibodies alone is only evidence of previous infection. Presence of IgM or IgG antibodies may reflect cross-reactivity with other flaviviruses or non-specific reactivity. Clinically compatible cases with the presence of IgG, but not IgM, should be evaluated for other etiologic agents. PRNT should be used to confirm all positive antibody tests to differentiate flavivirus infections. At the time of initial presentation, serum samples should be stored and tested at a later time with convalescent phase serum samples. Such testing is indicated for the retrospective diagnosis of infection with a specific agent rather than for initiating therapy. A fourfold or greater change in WNV-specific neutralizing antibody titer between acute- and convalescent-phase serum samples collected two to three weeks apart confirms acute infection. Virus culture and RT-PCR testing to detect WNV RNA in serum or CSF of clinically ill, immunocompetent patients have limited utility in diagnosing human WNV neuroinvasive disease due to the low level viremia present in most cases at the time of clinical presentation. However, these tests may prove useful in immunocompromised patients, in whom antibody development is delayed or absent. Negative virus culture and RT-PCR results should not be used to rule out an infection. Routine clinical laboratory studies are generally nonspecific. In patients with neuroinvasive disease, typical CSF findings, particularly in West Nile meningitis, include pleocytosis (generally less than 500 cells/mm 3 ) with elevated protein but normal glucose levels. Features of the pleocytosis that are 6
7 indicative of WNV infection include a prolonged predominance of polymorphonuclear cells and the presence of abnormal-appearing reactive lymphocytes or monocytes, including plasma cell-like and mollaret-like cells. Computed tomography (CT) and MRI are most frequently used to evaluate patients with possible CNS infection, with MRI being preferred when available. The incidence of acute MRI abnormalities in patients with WNV neuroinvasive disease has been extremely variable, but MRI may detect early changes in the basal ganglia, thalamus, and brainstem in approximately 30 percent of patients with encephalitis, and in the anterior spinal cord in patients with poliomyelitis. Diffusion-weighted MRI is superior to conventional MRI and is the preferred neuroimaging modality. CT with and without intravenous contrast administration should be used only if MRI is unavailable, impractical or cannot be performed. Prevention and treatment: There are no effective vaccines to prevent WNV infection. Several have completed phase I or phase II human clinical trials with promising results, but lack of predictability of the magnitude and location of outbreaks are problematic for designing phase III trials. Prevention includes avoiding mosquito bites (e.g., mosquito repellant and clothing) and reducing the number of mosquitos (e.g., eliminating standing water). There is no effective treatment for WNV infection. Milder cases are generally self-limiting or can be treated with over-the-counter medications to relieve symptoms such as pain and fever. In more severe cases, patients often need to be hospitalized to receive supportive treatment and rehabilitation to address neurological and cognitive consequences of CNS infection. There is empiric use without proof of benefit of several therapeutic modalities, including antiviral agents, nucleic acid analogues, missense sequences, immunomodulating agents and angiotensin-receptor blockers. Perinatal and reproductive considerations: Pregnant women are not at higher risk for WNV infection. Neither the proportion of WNV infections during pregnancy that result in congenital infection nor the spectrum of clinical abnormalities associated with congenital WNV infection is known. The risk of transmitting WNV through breastfeeding to the newborn appears to be very low. In light of the well-established health benefits of breastfeeding, there are no recommendations for a woman to stop breastfeeding because of WNV illness. Pregnant women and women who are breastfeeding should take preventive measures, including insect repellant, to reduce their risk for WNV infection (CDC 2015). CDC recommends clinical evaluation of infants born to mother with known or suspected WNV infection during pregnancy (See Appendix). Practitioners should delay donation of gametes from donors who have confirmed or suspected WNV infections until 14 days after the condition is resolved or 28 days from the onset of symptoms, 7
8 whichever is later. Donors who are not in good health, including those with recent significant fever and flu-like illnesses or recent viral meningitis, encephalitis or meningoencephalitis episodes, should be similarly deferred. Summary of clinical evidence: Citation CDC (2015b) WNV therapeutics CDC (2015c) Pregnancy & breastfeeding CDC (2013b) Guidelines for surveillance, prevention and control Tunkel (2008) for the IDSA Guideline-management of encephalitis Content, Methods, Recommendations Key points: No antiviral or adjunctive therapies are approved or recommended for treatment of WNV disease. Case reports and case series of various products (e.g., standard and hyperimmune polyclonal immune globulin, monoclonal immune globulin, interferon, ribavirin and corticosteroids) were inconclusive; controlled clinical trials have shown no benefit for infections due to WNV or closely related flavivirus infections. Key points: Pregnant women are not at higher risk for WNV infection. Risk of transmission from infected pregnant woman to fetus or newborn is low. Risk for WNV transmission through breastfeeding is unknown. Breastfeeding should be continued. Preventive measures, including insect repellant, should be used. Key points: No effective vaccine. Testing recommended for symptomatic individuals only. WNV IgM antibody assay is preferred initial screening test. o Confirm positive results using CDC-defined IgM and IgG ELISA and PRNT on specimens against other flaviviruses known to be active or be present in the area or in the region where the patient traveled. Virus isolation of CSF or serum and RT-PCR of serum or CSF to detect WNV RNA in clinically ill patients have limited utility in diagnosing human WNV neuroinvasive disease due to low level viremia present in most cases at clinical presentation. May be helpful in confirming human WNV infection in immunocompromised patients when antibody development is delayed or absent. Key points: Serum IgM recommended. Recommend storing serum for testing later with convalescent phase serum samples for retrospective diagnosis of infection with a specific agent. A 4-fold increase in convalescent-phase IgG antibody titers may be necessary to establish the diagnosis. CSF IgM recommended over CSF PCR due to superior sensitivity. PRNT recommended in areas where multiple flaviviridae co-circulate or in patients who have received previous vaccination against a related arbovirus. CSF virus culture not routinely recommended. NAATs preferred. Neuroimaging recommended for evaluating encephalitis. MRI superior to CT. T2- weighted and fluid-attenuated inversion recovery (FLAIR) MRI findings ( 30% of cases) preferred over standard MRI. May reveal hyperintense lesions in the substantia nigra, basal ganglia, and thalami; similar lesions in the spinal cord. o Use CT only if MRI unavailable. Supportive care only recommended. Ribavirin not recommended. 8
9 Citation ACR (2014) Practice parameter for MRI ASRMS (2008) Position statement for gamete donation CDC (2004) Content, Methods, Recommendations Key points: Key points: MRI recommended for infectious disorders: encephalitis, meningitis, abscess. Most commonly accepted protocols are T1-weighted sequence in the sagittal plane (or a T1-weighted volumetric acquisition) and T2-weighted fluid-attenuated inversion recovery (FLAIR) and fast spin-echo or turbo-spin-echo (or equivalent) sequences in the axial plane. o If FLAIR is not available or in children under the age of 2 years, proton density weighted sequences may be helpful. Under certain clinical circumstances, very rapid acquisitions such as echo planar imaging or single shot fast-spin-echo imaging can be performed to obtain T2 information. No definitive evidence linking WNV transmission with reproductive cells. Recommend practitioners defer gamete donors who have confirmed or suspected WNV infections (until 14 days after the condition is resolved or 28 days from the onset of symptoms, whichever is later). Donors who are not in good health, including those with recent significant fever and flulike illnesses or recent viral meningitis, encephalitis or meningoencephalitis episodes, should be similarly deferred. Key points: Infants with congenital exposure (see Appendix) Glossary Screening asymptomatic pregnant women for WNV infection not recommended. Recommend serum (and CSF, if clinically indicated) WNV antibody testing in pregnant women who have meningitis, encephalitis, acute flaccid paralysis, or unexplained fever in at-risk area: o If testing is positive, report to local or state health department, and women followed to determine pregnancy outcome. Consider detailed prenatal obstetrical ultrasound examination to evaluate for structural abnormalities no sooner than two to four weeks after onset of illness in the mother, unless earlier examination is otherwise indicated. Amniotic fluid, chorionic villi or fetal serum can be tested, but sensitivity, specificity, and predictive value are unknown, and the clinical consequences of fetal infection have not been determined. In cases of miscarriage or induced abortion, advise testing of all products of conception (e.g., the placenta and umbilical cord) for evidence of infection to document effects of WNV infection on pregnancy outcome. Recommend clinical evaluation of infant born to mother with known or suspected WNV infection during pregnancy. Consider further evaluation if any clinical abnormality found or laboratory testing indicates possible congenital WNV infection. Acute flaccid paralysis A heterogeneous neurologic condition affecting the anterior horn of the spinal cord. Defined by the onset of acute, areflexic or hyporeflexic weakness in one or more limbs and/or the cranial nerve-innervated muscles (e.g., seen in poliomyelitis and Guillain-Barré syndrome). Arbovirus A class of viruses transmitted to humans by arthropods such as mosquitoes and ticks. 9
10 Pleocytosis Elevated inflammatory cells in CSF (> 5 leukocytes/mm 3 ). May occur with peripheral leukocyte count >10,000/mm 3 or neuroimaging findings consistent with acute meningeal inflammation. West Nile encephalitis WNV infection of the brain parenchyma itself. More typically manifested in older or immunocompromised individuals. West Nile fever A symptom that occurs typically between two and 15 days after WNV infection. May occur in isolation or with other symptoms of WNV infection. West Nile meningitis WNV infection of the meninges (the outer covering of the brain and spinal cord). Comprises the largest percentage of neuroinvasive disease cases in younger age groups. West Nile poliomyelitis A form of acute flaccid paralysis resulting from WNV infection of the anterior horn cells of the spinal cord, leading to acute flaccid limb weakness. West Nile virus (WNV) A neurotropic species of flavivirus transmitted to humans mainly by Culex mosquitoes. Also transmitted by blood transfusions, organ transplantation or from mother to fetus or baby during pregnancy, delivery or breastfeeding. References Professional society guidelines/other: American Society for Reproductive Medicine/Society for Assisted Reproductive Technology position statement on West Nile virus. Fertil Steril. 2008; 90(5 Suppl): S ACR ASNR SPR Practice Parameter for the Performance and Interpretation of Magnetic Resonance Imaging (MRI) of the Brain. ACR website. Accessed June 17, CDC. Interim guidelines for the evaluation of infants born to mothers infected with West Nile virus during pregnancy. MMWR Morb Mortal Wkly Rep. 2004; 53(7): CDC. Pregnancy & Breastfeeding. Last updated March 31, CDC website. Accessed June 20, 2016.(c) CDC. West Nile virus disease therapeutics. Review of the literature for healthcare providers. Revised June 15, CDC National Center for Emerging and Zoonotic Infectious Diseases website. Accessed June 14, 2016.(b) 10
11 CDC. West Nile Virus in the United States: Guidelines for Surveillance, Prevention, and Control. 4th revision. June 14, CDC website. Accessed June 13, 2016.(b) Tunkel AR, Glaser CA, Bloch KC, et al. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2008; 47(3): Peer-reviewed references: 510(k) Premarket Notification using product code NOP. FDA website. Accessed June 17, Beasley DW. Vaccines and immunotherapeutics for the prevention and treatment of infections with West Nile virus. Immunotherapy. 2011; 3(2): CDC.General Questions About West Nile Virus. Last updated March 30, CDC website. Accessed June 13, 2016.(a) CDC. West Nile virus and other arboviral diseases--united States, MMWR Morb Mortal Wkly Rep. 2013; 62(25): (a) Debiasi RL, Tyler KL. West Nile virus meningoencephalitis. Nat Clin Pract Neurol. 2006; 2(5): Patel H, Sander B, Nelder MP. Long-term sequelae of West Nile virus-related illness: a systematic review. Lancet Infect Dis. 2015; 15(8): Sejvar JJ. Clinical manifestations and outcomes of West Nile virus infection. Viruses. 2014; 6(2): Tyler KL. Current developments in understanding of West Nile virus central nervous system disease. Curr Opin Neurol. 2014; 27(3): Clinical trials: Searched clinicaltrials.gov on June 20, 2016 using terms West Nile virus all studies. 19 studies found, two still active but not recruiting. Evaluating the Safety and Immunogenicity of a Live Attenuated West Nile Virus Vaccine for West Nile Encephalitis in Adults 50 to 65 Years of Age. ClinicalTrials.gov website. Published July 8, Updated December 14, Accessed June 20,
12 Phase 1 Trial of Inactivated West Nile Virus Vaccine. ClinicalTrials.gov website. Published January 8, Updated June 16, Accessed June 20, CMS National Coverage Determinations (NCDs): No NCDs identified as of the writing of this policy. Local Coverage Determinations (LCDs): L34175 Ophthalmic Angiography (Fluorescein and Indocyanine Green). CMS website. Accessed June 20, L34426 Ophthalmic Angiography (Fluorescein and Indocyanine Green). CMS website. Accessed June 20, A52446 Intravenous Immune Globulin (IVIG) - Related to LCD L CMS website. Accessed June 20, IVIG is covered when used in the treatment of WNV infection, including meningitis and encephalitis. Commonly submitted codes Below are the most commonly submitted codes for the service(s)/item(s) subject to this policy. This is not an exhaustive list of codes. Providers are expected to consult the appropriate coding manuals and bill accordingly. CPT Code Description Comments West Nile virus, IgM West Nile virus ICD-10 Description Code A West Nile virus 39 Z Exposure to communicable viral disease Comments HCPCS Code Description Comments 12
13 Appendix. CDC interim guidelines for the evaluation of WNV infection in infants born to mothers infected with WNV during pregnancy (2004) 1 13
14 14
15 1 Adapted from CDC (2004). 15
Clinical Policy Title: West Nile virus
Clinical Policy Title: West Nile virus Clinical Policy Number: CCP.1251 Effective Date: October 1, 2016 Initial Review Date: July 20, 2016 Most Recent Review Date: July 3, 2018 Next Review Date: July 2019
More informationClinical Policy Title: West Nile virus
Clinical Policy Title: West Nile virus Clinical Policy Number: 17.01.07 Effective Date: October 1, 2016 Initial Review Date: July 20, 2016 Most Recent Review Date: August 16, 2017 Next Review Date: July
More informationWest Nile Virus. By Frank Riusech
West Nile Virus By Frank Riusech Disease Etiology: West Nile virus(wnv), genus, flavivirus is positive- stranded RNA arbovirus (arthropod- borne), belonging to the Flaviviridae family. Included in this
More informationClinical Policy Title: Zoster (shingles) vaccine
Clinical Policy Title: Zoster (shingles) vaccine Clinical Policy Number: 18.02.10 Effective Date: June 1, 2018 Initial Review Date: April 10, 2018 Most Recent Review Date: May 1, 2018 Next Review Date:
More informationCase Classification West Nile Virus Neurological Syndrome (WNNS)
WEST NILE VIRUS Case definition Case Classification West Nile Virus Neurological Syndrome (WNNS) CONFIRMED CASE West Nile Virus Neurological Syndrome (WNNS) Clinical criteria AND at least one of the confirmed
More informationAppendix I (a) Human Surveillance Case Definition (Revised July 4, 2005)
Section A: Case Definitions Appendix I (a) Human Surveillance Case Definition (Revised July 4, 2005) The current Case Definitions were drafted with available information at the time of writing. Case Definitions
More informationClinical Information on West Nile Virus (WNV) Infection
Clinical Information on West Nile Virus (WNV) Infection Introduction In 1999, West Nile Virus (WNV), an Old World flavivirus, producing a spectrum of disease including severe meningoencephalitis, appeared
More informationMosquitoborne Viral Diseases
Mosquitoborne Viral Diseases Originally prepared by Tom J. Sidwa, D.V.M, M.P.H State Public Health Veterinarian Zoonosis Control Branch Manager Texas Department of State Health Services 1 AGENT Viruses
More informationWhat s Lurking out there??????
What s Lurking out there?????? Dave Warshauer, PhD, D(ABMM) Deputy Director, Communicable Diseases Wisconsin State Laboratory of Hygiene david.warshauer@slh.wisc.edu WISCONSIN STATE LABORATORY OF HYGIENE
More informationAppendix B: Provincial Case Definitions for Reportable Diseases
Ministry of Health and Long-Term Care Infectious Diseases Protocol Appendix B: Provincial Case Definitions for Reportable Diseases Disease: West Nile Virus Illness Revised March 2017 West Nile Virus Illness
More informationCarol M. Smith, M.D., M.P.H. Commissioner of Health and Mental Health Ulster County Department of Health and Mental Health May 20, 2016
Carol M. Smith, M.D., M.P.H. Commissioner of Health and Mental Health Ulster County Department of Health and Mental Health May 20, 2016 Michael Hein County Executive Zika virus was first discovered in
More informationZIKA VIRUS OUTBREAK. JANET B. EDDY M.D. KU-WICHITA PGY2 OBSTETRICS AND GYNECOLOGY RESIDENCY Dominican Republic 2016
ZIKA VIRUS OUTBREAK JANET B. EDDY M.D. KU-WICHITA PGY2 OBSTETRICS AND GYNECOLOGY RESIDENCY Dominican Republic 2016 Zika time line 1947: 1 st isolated in rhesus monkey in Zika forest of Uganda 1 12/2013:
More informationQuestions and Answers for Pediatric Healthcare Providers: Infants and Zika Virus Infection
1 of 5 01/02/2016 20:39 Questions and Answers for Pediatric Healthcare Providers: Infants and Zika Virus Infection Summary CDC has developed interim guidelines for healthcare providers in the United States
More informationClinical Policy Title: Strep testing
Clinical Policy Title: Strep testing Clinical Policy Number: 07.01.09 Effective Date: December 1, 2017 Initial Review Date: October 19, 2017 Most Recent Review Date: November 16, 2017 Next Review Date:
More informationZIKA VIRUS TESTING GUIDANCE, UPDATED 7/20/2016
Section 1: Which patients should be offered testing? SUMMARY OF CATEGORIES OF PATIENTS WHO SHOULD BE TESTED FOR ZIKA 1) Pregnant women who traveled to a Zika-affected area (see link to current list in
More informationClinical Policy: Diagnostic Testing for Zika Virus Reference Number: CP.MP.111 Effective Date: 06/16
Clinical Policy: Diagnostic Testing for Zika Virus Reference Number: CP.MP.111 Effective Date: 06/16 Last Review Date: 05/16 Revision Log See Important Reminder at the end of this policy for important
More informationZika Virus. Robert Wittler, MD
Zika Virus Robert Wittler, MD Disclosure I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services discussed in this CME
More informationZika Virus. Disclosure. Zika Virus 8/26/2016
Zika Virus Robert Wittler, MD Disclosure I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services discussed in this CME
More informationZika Virus and Control Efforts in Arizona
Zika Virus and Control Efforts in Arizona Irene Ruberto, MPH, PhD Epidemiologist Office of Infectious Disease Services Arizona Department of Health Services November 10, 2016 Goal by Humbletree (cc by-nc
More informationCouncil of State and Territorial Epidemiologists Position Statement
04-ID-01 Committee: Title: Infectious Disease Revision of the National Surveillance Case Definition of Diseases Caused by Neurotropic Domestic Arboviruses, Including the Addition to the NNDSS of Non-Neuroinvasive
More informationGuidance for Investigation and Management of Zika Virus Infection
Guidance for Investigation and Management of Zika Virus Infection Update: February 11, 2016 Public Health Agency of Canada has issued recommendations from the Committee to Advise on Tropical Medicine and
More informationMercer MRC A Newsletter for and about our volunteers
Mercer MRC A Newsletter for and about our volunteers May 2017 Volume 1, Issue 5 Brian Hughes, County Executive Marygrace Billek, Director, Dept. of Human Services Lyme Disease Awareness Month May is Lyme
More informationZika Virus Guidance for Medical Providers. Denise Smith, PHN, MPA Director of Disease Control Kern County Public Health Services Department
Zika Virus Guidance for Medical Providers Denise Smith, PHN, MPA Director of Disease Control Kern County Public Health Services Department Kern Perinatal Symposium March 3, 2017 CME DISCLOSURE The Planners,
More informationZika Virus: The Olympics and Beyond
Zika Virus: The Olympics and Beyond Alice Pong, MD Pediatric Infectious Diseases Rady Children s Hospital-San Diego University of California, San Diego Disclosures I have no disclosures to report 1 Objectives
More informationPublic Health Image Library. CDC/ Cynthia Goldsmith. Image #
Zika Virus Fredrick M. Abrahamian, D.O., FACEP, FIDSA Clinical Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar,
More informationUpdates in Infectious Diseases. Kelley Struble, DO, MS St. John Physicians Infectious Disease September 30, 2016
Updates in Infectious Diseases Kelley Struble, DO, MS St. John Physicians Infectious Disease September 30, 2016 Disclosures No financial relationships or affiliations to disclose Overview Activity Pre-Test
More informationClinical Policy Title: Zika virus
Clinical Policy Title: Zika virus Clinical Policy Number: 17.01.04 Effective Date: October 1, 2016 Initial Review Date: May 18, 2016 Most Recent Review Date: June 22, 2017 Next Review Date: June 2018 Policy
More informationClinical Policy Title: Zika virus
Clinical Policy Title: Zika virus Clinical Policy Number: 17.01.04 Effective Date: October 1, 2016 Initial Review Date: May 18, 2016 Most Recent Review Date: May 18, 2016 Next Review Date: May 2017 Policy
More informationSHASTA COUNTY Health and Human Services Agency
FROM: 530 229 8447 TO: 15302293984 08/06/14 12:30 Pg 1 of 5 especially SHASTA COUNTY Health and Human Services Agency Public Health 2650RreslauerWay Redding, CA 96001-4297 (530) 229-8484 FAX (530) 225-3743
More informationZika Virus in the Primary Care Setting
Zika Virus in the Primary Care Setting Monica McArthur, MD PhD Assistant Professor of Pediatrics Center for Vaccine Development University of Maryland School of Medicine Maryland Chapter ACP Meeting 17
More informationThis memo is intended to provide information to NC clinicians and laboratories regarding diagnosis, management and reporting of Zika virus infection.
May 18, 2016 (replaces version dated March 31, 2016) To: From: North Carolina Health Care Providers and Laboratories Megan Davies, MD, State Epidemiologist Scott Zimmerman, DrPH, MPH, HCLD (ABB), State
More informationWhat is Zika virus? What are the symptoms and complications of Zika virus infection? Are cases expected in Canada?
What is Zika virus? Zika Virus Update for Healthcare Professionals Updated June 22, 2016; italicized text indicates clarification of wording contained in previous versions. Zika virus is a Flavivirus transmitted
More informationCenters for Disease Control and Prevention Zika Virus in Pregnancy What Midwives Need To Know
Centers for Disease Control and Prevention Zika Virus in Pregnancy What Midwives Need To Know Margaret A. Lampe, RN, MPH Pregnancy and Birth Defects Surveillance Team Zika Virus Emergency Response U.S.
More informationZika: Deet, There It Is. Anna Powell, MD Reproductive Infectious Disease Fellow THEGOS
Zika: Deet, There It Is Anna Powell, MD Reproductive Infectious Disease Fellow THEGOS Disclosure I have no financial disclosures or conflicts of interest Lessons from Rubella At peak of rubella epidemic
More informationZIKA UPDATE NOVEMBER Ministry of Health, Barbados
ZIKA UPDATE NOVEMBER 2016 Ministry of Health, Barbados Zika Virus Disease Objectives By the end of this presentation you should be able: To recount the track of the current global Zika virus epidemic To
More informationFY 2017 President s Budget Request Overview for the National Center on Birth Defects and Developmental Disabilities
National Center on Birth Defects and Developmental Disabilities FY 2017 President s Budget Request Overview for the National Center on Birth Defects and Developmental Disabilities Sascha Chaney Associate
More informationZIKA VIRUS. John J. Russell MD May 27, 2016
John J. Russell MD May 27, 2016 HISTORY Discovered 1947 Zika Forest of Uganda in rhesus monkeys, thus the name Found in humans in Africa in 1952 Not considered a public health threat until outbreak in
More informationWest Nile Fever. F. Karup Pedersen 2012
F. Karup Pedersen 2012 West Nile virus first isolated 1937 in West Nile district, Uganda Japanese encephalitis reconvalescens serum could neutralize West Nile virus Virus antigenically related to Japanese
More informationTREATING THE REHAB PATIENT WITH WEST NILE VIRUS. Amy J. Wilson MD Medical Director, Baylor Institution of Rehabilitation January 2014
TREATING THE REHAB PATIENT WITH WEST NILE VIRUS Amy J. Wilson MD Medical Director, Baylor Institution of Rehabilitation January 2014 FIGHT THE BITE! OBJECTIVES 1. Review local incidence of West Nile virus
More informationZika Virus. ZIKA VIRUS & PREGNANCY Stephen Champlin, M.D. FLAVIVIRIDAE VIRUS SPECTRUM. Virus family Flaviviridae
ZIKA VIRUS & PREGNANCY Stephen Champlin, M.D. Zika Virus Virus family Flaviviridae Positive sense, single-stranded RNA virus FLAVIVIRIDAE VIRUS SPECTRUM Arbovirus - spread by arthropods to mammals Flaviviridae
More informationZIKA Jordan H. Perlow MD Banner University Medical Center Division of Maternal Fetal Medicine Phoenix Perinatal Asoociates
ZIKA Jordan H. Perlow MD Banner University Medical Center Division of Maternal Fetal Medicine Phoenix Perinatal Asoociates Disclosures I have no relevant financial relationships to disclose or conflicts
More informationCDC Responds to ZIKA Zika 101
CDC Responds to ZIKA Zika 101 Updated April 29, 2016 What is Zika virus disease (Zika)? Disease spread primarily through the bite of an Aedes species mosquito infected with Zika virus. Many people infected
More informationWest Nile Virus in Maricopa County
West Nile Virus in Maricopa County A Culex quinquefasciatus mosquito on a human finger. Image by James Gathany/ CDC gov/ public domain Maricopa County Department of Public Health Office of Epidemiology
More informationOutbreak Investigation Guidance for Vectorborne Diseases
COMMUNICABLE DISEASE OUTBREAK MANUAL New Jersey s Public Health Response APPENDIX T3: EXTENDED GUIDANCE Outbreak Investigation Guidance for Vectorborne Diseases As per N.J.A.C. 8:57, viruses that are transmitted
More informationZika virus infection Interim clinical guidance for Primary Care
Zika virus infection Interim clinical guidance for Primary Care Zika virus infection is a notifiable disease in Ireland under the Infectious Diseases (Amendment) Regulations 2016 (S.I.. 276 of 2016). All
More informationZika 101 for Occupational Safety and Health Professionals
CDC Responds to ZIKA Zika 101 for Occupational Safety and Health Professionals CDR Jill M. Shugart, MSPH, REHS CDC/National Institute for Occupational Safety and Health Emergency Preparedness and Response
More informationClinical Policy Title: Seasonal influenza testing
Clinical Policy Title: Seasonal influenza testing Clinical Policy Number: 07.01.08 Effective Date: October 1, 2017 Initial Review Date: August 17, 2017 Most Recent Review Date: September 21, 2017 Next
More informationZika Virus. Centers for Disease Control and Prevention
Centers for Disease Control and Prevention Zika Virus Ingrid Rabe Medical Epidemiologist Arboviral Diseases Branch Centers for Disease Control and Prevention February 1, 2016 Zika Virus Single stranded
More informationClinical Policy Title: Genicular nerve block
Clinical Policy Title: Genicular nerve block Clinical Policy Number: 14.01.10 Effective Date: October 1, 2017 Initial Review Date: September 21, 2017 Most Recent Review Date: October 19, 2017 Next Review
More informationClinical Policy Title: Cardiac rehabilitation
Clinical Policy Title: Cardiac rehabilitation Clinical Policy Number: 04.02.02 Effective Date: September 1, 2013 Initial Review Date: February 19, 2013 Most Recent Review Date: February 6, 2018 Next Review
More informationFact Sheet for Health Care Providers: Interpreting Results from the Aptima Zika Virus assay. September 7, 2016
Dear Health Care Provider: Fact Sheet for Health Care Providers: Interpreting Results from the Aptima Zika Virus assay September 7, 2016 The U.S. Food and Drug Administration (FDA) has issued an Emergency
More informationEuropean Centre for Disease Prevention and Control. Zika virus disease
European Centre for Disease Prevention and Control Zika virus disease Stockholm, 19 February 2016 Background information Zika virus is a member of the Flaviviridae family and transmitted by mosquitoes
More informationZika. Nicole Evert, MS Zoonosis Control Branch Department of State Health Services Austin, Texas
Zika Nicole Evert, MS Zoonosis Control Branch Department of State Health Services Austin, Texas Family Flaviviridae, genus Flavivirus Vectors: Aedes aegypti and Aedes albopictus Maintained in a human-mosquito-human
More informationZIKA VIRUS. Epic and aspects of management
ZIKA VIRUS Epic and aspects of management Classification - Belong to the family Flaviviridae which are mosquitoes borne viruses such as Dengue virus ( DEN V ), West Nile virus ( WN V ), Yellow fever Virus
More informationZika Virus Basics. Flaviviridae Flavivirus Disease Vector Vaccine *Dengue (serotypes 1-4) Zika Virus Basics. Zika Virus Transmission Cycle
Zika: Infection,, and Protection Roxanne P. Liles, Ph.D., MLS(ASCP) CM Assistant Professor of Biology Louisiana State University at Alexandria 318-473-6518 rliles@lsua.edu Zika Virus Basics Virion: Enveloped
More informationAn Introduction to Dengue, Zika and Chikungunya Viruses
An Introduction to Dengue, Zika and Chikungunya Viruses Natalie Marzec, MD, MPH Zoonoses Epidemiologist 2017 Global Health and Disasters Course Objectives Arbovirus Overview Public Health Activities Clinical
More information3/24/2017. CDC S Response to Zika ZIKA 101. Updated February 2, 2017 INTRODUCTION
CDC S Response to Zika ZIKA 101 Updated February 2, 2017 INTRODUCTION 1 What is Zika? Zika virus is spread to people primarily through the bite of an infected Aedes species mosquito (Ae. aegypti and Ae.
More informationDilemmas in the Management of Meningitis & Encephalitis HEADACHE AND FEVER. What is the best initial approach for fever, headache, meningisums?
Dilemmas in the Management of Meningitis & Encephalitis Paul D. Holtom, MD Professor of Medicine and Orthopaedics USC Keck School of Medicine HEADACHE AND FEVER What is the best initial approach for fever,
More informationGeneral Description. Significance
General Description The Zika virus is a member of the Flavivirus family, and is a small, enveloped virus (easy to kill with a hospital disinfectant). Zika virus is an emerging mosquito-borne virus that
More informationZika Virus What Every Woman Needs to Know
Zika Virus What Every Woman Needs to Know Carrie L. Byington, MD The Jean and Thomas McMullin Professor and Dean of Medicine Senior Vice President Health Science Center Vice Chancellor for Health Services
More informationWrapping Our Heads Around the Outbreak
Wrapping Our Heads Around the Outbreak An Update on the Zika Virus P. Zach White, PharmD PGY1 Pharmacy Resident Mayo Eugenio Litta Children s Hospital Pharmacy Grand Rounds June 7, 2016 2015 MFMER slide-1
More informationWest Nile Virus in Maricopa County
West Nile Virus in Maricopa County Maricopa County Department of Public Health Office of Epidemiology July 21 January 1, 29 December 31, 29 Commentary West Nile virus (WNV) is a mosquito-borne virus that
More informationZika Virus Identifying an Emerging Threat. Florida Department of Health in Miami-Dade County Epidemiology, Disease Control, & Immunization Services
Zika Virus Identifying an Emerging Threat Florida Department of Health in Miami-Dade County Epidemiology, Disease Control, & Immunization Services What is Zika Virus? Zika virus is a vector-borne disease
More informationWest Nile Virus Los Angeles County
West Nile Virus Los Angeles County Rachel Civen, M.D., M.P.H., F.A.A.P. Medical Epidemiologist County of Los Angeles Department of Public Health D16:\WNV_Tarzana_July 2012.ppt No. 2 WNV ECOLOGY Virus maintained
More informationWhen infections go viral Zika Virus
When infections go viral Zika Virus John Fangman, MD Associate Professor of Medicine (Infectious Diseases) Senior Medical Director of Ambulatory, Medical College Physicians Medical College of Wisconsin
More informationClinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening
Clinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening Clinical Policy Number: 01.01.02 Effective Date: April 1, 2015 Initial Review Date: January 21, 2015 Most Recent
More informationFirst Probable West Nile Virus Case in the Simcoe-Muskoka Area
Dr. Charles Gardner, Medical Officer of Health Dr. Colin Lee, Associate Medical Officer of Health Dr. Lisa Simon, Associate Medical Officer of Health First Probable West Nile Virus Case in the Simcoe-Muskoka
More informationZika Virus. Maternal & Fetal Effects. John P. Elliott, MD Medical Director, Valley Perinatal Services Phoenix, Arizona
Zika Virus Maternal & Fetal Effects John P. Elliott, MD Medical Director, Valley Perinatal Services Phoenix, Arizona Objective of Presentation Sneeka Peeka at Zika Disclosure I have nothing to disclose
More informationWest Nile Virus in Maricopa County
West Nile Virus in Maricopa County Culex larvae found collecting in standing water Image by CDC/James Gathany - License: Public Domain. Maricopa County Department of Public Health Office of Epidemiology
More informationWest Nile Virus in Maricopa County
West Nile Virus in Maricopa County Maricopa County Department of Public Health Office of Epidemiology July 2009 January 1, 2008 December 31, 2008 Commentary West Nile virus (WNV) is a mosquito-borne virus
More informationModule Three About Zika Virus: What is Known and Not Known
Module Three About Zika Virus: What is Known and Not Known HOUSEKEEPING For educational and quality improvement purposes, this TeleECHO Clinic will be recorded By participating in this clinic, you are
More informationAs suggested by one fellow student, please consider the CDC's "Final Rules for Control of Communicable Diseases: Interstate and Foreign
As suggested by one fellow student, please consider the CDC's "Final Rules for Control of Communicable Diseases: Interstate and Foreign http://www.cdc.gov/quarantine/ aboutlawsregulationsquarantineisolatio
More informationRelevant Communicable Diseases in HCT/Ps
Relevant Communicable Diseases in HCT/Ps Phyllis I. Warkentin, MD Professor of Pathology and Pediatrics University of Nebraska Medical Center FACT Chief Medical Officer Relevant Communicable Diseases in
More informationZika and Emerging Infectious Diseases. Clifford T. Mauriello, MD, FAAP Assistant Clinical Professor May 31, 2016
Zika and Emerging Infectious Diseases Clifford T. Mauriello, MD, FAAP Assistant Clinical Professor May 31, 2016 Famous Last Words The time has come to close the book on infectious diseases. We have basically
More informationConsiderations for Risk Associated with Zika Virus (ZIKV) Background Document
The following information will be used for a one-hour meeting on February 15, 20 of AATB s Tissue Transmitted Diseases Advisory Group (TTDAG), a subgroup of the Physicians Council. Questions: 1. Should
More informationZIKA PRESENTED BY DENNIS QUERTERMOUS, DIANNA HUNTER, MERCEDES RUTLEDGE, AND DRE'ANDRIA THOMPSON
ZIKA PRESENTED BY DENNIS QUERTERMOUS, DIANNA HUNTER, MERCEDES RUTLEDGE, AND DRE'ANDRIA THOMPSON ZIKA OVERVIEW Family: Flaviviridae Genus: Flavivirus Enveloped, single-stranded RNA virus First identified
More informationZika virus: Interim guidance information for LMCs (midwives), GPs and other health professionals dealing with Zika virus in pregnancy 5 February 2016
Zika virus: Interim guidance information for LMCs (midwives), GPs and other health professionals dealing with Zika virus in pregnancy 5 February 2016 This interim guidance is the result of consultation
More informationEDUCATIONAL COMMENTARY EMERGING INFECTIOUS DISEASES WITH GLOBAL IMPACT
Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits click on Earn CE Credits under Continuing Education on
More informationWest Nile Virus in the Region of Peel 2002
HUMAN CASE SURVEILLANCE Introduction Human illness caused by mosquito-borne WNV acquired in Peel occurred for the first time in 2002. In 1999, a Peel resident who had traveled to New York City acquired
More informationTHE ZIKA VIRUS. August 3, Sonia G. Pandit, MPH MBA Chief Executive Officer The Pandit Group
THE ZIKA VIRUS August 3, 2016 Sonia G. Pandit, MPH MBA Chief Executive Officer The Pandit Group sonia@thepanditgroup.com 443-990-1372 www.thepanditgroup.com What Makes Zika Unique? Viral disease (Flavi
More informationZika Virus Update. Partner Webinar 05/12/2016
Zika Virus Update Partner Webinar 05/12/2016 Today s presenters Patricia Quinlisk, MD, MPH, Medical Director /State Epidemiologist Ann Garvey, DVM, MPH, MA, State Public Health Veterinarian/ Deputy State
More informationEverything you ever wanted to know about Zika Virus Disease
Everything you ever wanted to know about Zika Virus Disease (in 14 slides) Jon Temte, MD/PhD University of Wisconsin School of Medicine and Public Health 28 January 2016 Zika Virus mosquito-borne flavivirus
More informationPresentation Overview
Presentation Overview Characteristics of Zika virus Characteristics of Zika virus infection Epidemiology and outbreaks Vector and transmission Clinical symptoms Diagnosis and testing Treatment and prevention
More informationEuropean Guidelines on Management of Tick Borne Encephalitis: a Focus on Intensive Care
European Guidelines on Management of Tick Borne Encephalitis: a Focus on Intensive Care Pille Taba MD, PhD University of Tartu, Estonia Tallinn, 12 September 2014 Why tick borne encephalitis (TBE) guidelines?
More informationClinical Policy Title: Measurement of serum antibodies to infliximab and adalimumab
Clinical Policy Title: Measurement of serum antibodies to infliximab and adalimumab Clinical Policy Number: 01.01.03 Effective Date: January 1, 2016 Initial Review Date: September 16, 2015 Most Recent
More informationZika Virus Update for Emergency Care Providers
Zika Virus Update for Emergency Care Providers What is this Zika Virus? Jeff Doerr Epidemiologist Southeastern Idaho Public Health Zika Virus Single stranded RNA virus Genus Flavivirus, Family Flaviviridae
More informationHuman Case Investigation Report for West Nile Virus
Appendix I (e) Human Case Investigation Report for West Nile Virus Ministry of Health and Long-Term Care Ministere de la Santé et des Soins de longue durée Human Case Investigation Report for West Nile
More informationThomas McGee, L.C. 920 Main Street, Suite 1700 Kansas City, MO (816) * Toll Free (800) WEST NILE VIRUS
Thomas McGee, L.C. 920 Main Street, Suite 1700 Kansas City, MO 64105 (816) 842-4800 * Toll Free (800) 423-9044 www.thomasmcgee.com WEST NILE VIRUS What Is West Nile Virus (WNV)? Potentially serious illness
More informationZika Outbreak Discussion
Zika Outbreak Discussion May 10, 2016 2016 Zurich Healthcare Customer Symposium Speakers Krishna Lynch Senior Healthcare Risk Consultant Zurich Clayton Shoup Business Director, Workers Compensation Zurich
More informationInterim Guidelines for Pregnant Women During a Zika Virus Outbreak United States, 2016
1 of 7 01/02/2016 20:32 Interim Guidelines for Pregnant Women During a Zika Virus Outbreak United States, 2016 Weekly / January 22, 2016 / 65(2);30 33 On January 19, 2016, this report was posted as an
More informationFigure 1: Suspected and confirmed Zika virus cases reported by countries and territories in the Americas, by epidemiological week (EW)
Zika - Epidemiological Update 17 March 2016 Zika virus Incidence and trends Available data reported suggests a downward trend in reporting of Zika virus cases in the Region of the Americas (Figure 1).
More informationMosquito Control Matters
Mosquito Control Matters Gary Goodman General Manager Sacramento-Yolo Mosquito & Vector Control District Sacramento Yolo Mosquito & Vector Control District To provide safe, effective and economical mosquito
More informationUpdate on Transfusion- Transmitted Infectious Diseases
Update on Transfusion- Transmitted Infectious Diseases Scott Koepsell MD PhD Associate Professor University of Nebraska Medical Center I have no conflicts of interest to disclose. Global changes and the
More informationTitle: Revision to the Standardized Surveillance and Case Definition for Acute Flaccid Myelitis
17-ID-01 Committee: Infectious Disease Title: Revision to the Standardized Surveillance and Case Definition for Acute Flaccid Myelitis I. Statement of the Problem Acute flaccid myelitis (AFM) is a syndrome
More informationFight the Bite Zika Virus Webinar District of Columbia Department of Health
Fight the Bite Zika Virus Webinar District of Columbia Department of Health August 2016 Zika Virus Background and Tracking in Washington, DC, and Surrounding States Andrew Hennenfent, DVM, MPH DC Department
More informationEpidemiological Profile of West Nile Virus in Kent County, Michigan
Summary Report: Epidemiological Profile of West Nile Virus in Kent County, Michigan Dedicated to the 2002 Victims of the West Nile Virus in Kent County Contents Introduction.2 Section I: Understanding
More informationZika Virus Dr Conor Doherty
Zika Virus Dr Conor Doherty Zika Virus Single stranded RNA enveloped icosahedral virus Flavivirus (e.g. dengue, yellow feve er) First described in Zika forest in Uganda in 1947 Initial enzootic monkey
More information